People

Found 59,843 articles

• Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

  5/8/2023

  Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development.

• NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

  5/8/2023

  NLS Pharmaceutics Ltd. today announced that Keith Harrison Dewedoff has been appointed to the position of Interim Chief Financial Officer.

• AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer

  5/8/2023

  AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).

• Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

  5/8/2023

  Marker Therapeutics, Inc. today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.

• Zevra Announces Board of Directors and Leadership Changes

  5/8/2023

  Zevra Therapeutics, Inc. today announced changes to the Company’s Board of Directors (“Board”) and leadership. At the Company’s recent 2023 Annual Meeting of Stockholders (“Annual Meeting”), Zevra shareholders elected John B. Bode, Douglas W. Calder and Corey Watton to Zevra’s Board.

• Nephros Announces CEO Retirement and Succession Plan

  5/8/2023

  Nephros, Inc. today announced that Andy Astor, President and Chief Executive Officer, will retire in the coming months, and that Robert Banks will be named President and Chief Executive Officer effective on the first business day after the filing of Nephros’ Form 10-Q for the quarter ended March 31, 2023.

• Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's Plan

  5/8/2023

  Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter highlighting the strength of its Board and noting that Carl Icahn's "plan" for Illumina is sloppy and uninformed.

• Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

  5/7/2023

  Exelixis, Inc. announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately.

• The board member Philipp von Hugo resigns from Immunovia's board at his own request

  5/6/2023

  Philipp von Hugo, member of the board of directors of Immunovia AB, has at his own request notified his resignation from the Board of Directors of the Company and therefore declines re-election at annual general meeting on 26 May 2023.

• Feinstein Institutes’ 2023 Ross Prize awarded to fatty liver disease geneticists

  5/5/2023

  The Feinstein Institutes for Medical Research has selected two scientists from the University of Texas Southwestern Medical Center, Helen H. Hobbs, MD, and Jonathan C. Cohen, PhD, to receive the 10th annual Ross Prize in Molecular Medicine for groundbreaking research in dyslipidemias and metabolic liver disease.

• Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Jaguar Health, Inc. today announced that, effective May 2, 2023, the Company granted 100 restricted stock units (RSUs) to New Employee 1 and 4,000 RSUs to New Employee 2.

• Amador Bioscience Welcomes Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology

  5/5/2023

  Amador Bioscience has announced the appointment of Dr. Lorin Roskos as Chief Scientific Officer (CSO) and President of Quantitative Clinical Pharmacology (QCP).

• Rhythm Pharmaceuticals Announces New Employment Inducement Grants - May 5, 2023

  5/5/2023

  Rhythm Pharmaceuticals, Inc. today announced that on May 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 76,440 shares of its common stock to 16 new employees.

• Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Apellis Pharmaceuticals, Inc. today announced that the company approved the grant of equity awards to 13 new employees with a grant date of May 1, 2023.

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Fulcrum Therapeutics, Inc. today announced that the Company granted non-statutory stock options to new employees.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees.

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Curis, Inc. today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Development Officer, Jonathan B. Zung , Ph.D. to purchase a total of 500,000 shares of Curis common stock, with a grant date of May 1, 2023 (the "Inducement Grant").

• Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez

  5/5/2023

  It is with deep sadness that Aerami Therapeutics (“Aerami”) today announces that our dear friend, fierce patient advocate, dedicated mentor, and CEO, Lisa Yañez suddenly passed away on Tuesday, May 2, 2023.

• Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting Officer

  5/5/2023

  Ginkgo Bioworks Holdings, Inc.today announced the appointment of Steven P. Coen, CPA, a seasoned finance executive with more than 30 years of public accounting and corporate finance leadership experience, as Chief Accounting Officer ("CAO"), effective May 15, 2023.

• Prostatype Genomics appoints Professor Gerald Andriole as Chief Medical Officer

  5/5/2023

  Prostatype Genomics AB announced that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics.